INCA033989

DRUG4 trials

Sponsors

Incyte Corporation

Conditions

Essential ThrombocythemiaHealthy ParticipantsMyeloproliferative Neoplasms

Phase 1

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

Active, not recruitingNCT05936359

Incyte CorporationMyeloproliferative Neoplasms

Start: 2023-09-25End: 2028-02-29Updated: 2026-08-10

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

RecruitingNCT06034002

Incyte CorporationMyeloproliferative Neoplasms

Start: 2023-12-04End: 2028-10-29Target: 290Updated: 2026-04-17

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants

RecruitingNCT07448155

Incyte CorporationHealthy Participants

Start: 2026-03-19End: 2026-10-19Target: 126Updated: 2026-07-08

Phase 3

A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

RecruitingNCT07623200

Incyte CorporationEssential Thrombocythemia

Start: 2026-09-08End: 2030-11-01Target: 426Updated: 2026-09-14

Related Papers

Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia

Blood2025-11-03

Molecular characterization of patients (pts) with myeloproliferative neoplasms treated with INCA033989 demonstrates selective targeting of CALR mutant hematopoietic cells

Blood2025-11-03

Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies

Blood2025-11-03

Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy.

2025-01-201 citations